Current and future management options for myelodysplastic syndromes.
about
Hematologic complications, healthcare utilization, and costs in commercially insured patients with myelodysplastic syndrome receiving supportive care.Systematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia.Romiplostim dose-response in patients with myelodysplastic syndromesAge-related epigenetic drift in the pathogenesis of MDS and AML.Antitumor activity of a small-molecule inhibitor of the histone kinase HaspinPharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy.
P2860
Current and future management options for myelodysplastic syndromes.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Current and future management options for myelodysplastic syndromes.
@en
Current and future management options for myelodysplastic syndromes.
@nl
type
label
Current and future management options for myelodysplastic syndromes.
@en
Current and future management options for myelodysplastic syndromes.
@nl
prefLabel
Current and future management options for myelodysplastic syndromes.
@en
Current and future management options for myelodysplastic syndromes.
@nl
P2093
P50
P1433
P1476
Current and future management options for myelodysplastic syndromes.
@en
P2093
Hillary Prescott
Jean-Pierre Issa
Jeffrey Bryan
P2860
P304
P356
10.2165/11537920-000000000-00000
P577
2010-07-01T00:00:00Z
P6179
1018918929